Further PolyXen® Technology Patent


 

TIDMLPX 
 
RNS Number : 9059N 
Lipoxen PLC 
21 June 2010 
 

+---------------------------------+---------------------------------+ 
| FOR IMMEDIATE RELEASE           |                    21 June 2010 | 
+---------------------------------+---------------------------------+ 
 
 
                                  Lipoxen plc 
                          ('Lipoxen' or 'the Company') 
 
                        Further PolyXenTechnology Patent 
 
         - PolyXen  patent family strengthened and extended into 2025 - 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, announces today that its monofunctional PSA PolyXen technology grant 
has been allowed. The patent extends the PolyXen  technology patent family in 
the US giving both Lipoxen and its license partners additional patent protection 
into 2025. 
 
The monofunctional PSA technology is similar to Lipoxen's other PolyXen 
technologies as it enables the attachment of polysialic acid (PSA, a polymer 
occurring naturally in humans) to a therapeutic protein, thereby extending its 
active life. This process is known as polysialylation and improves drug 
performance and longer circulation time of the drug in the body. The resulting 
conjugate molecules are biodegradable, non-immunogenic and non-toxic, and 
therefore are expected to avoid the toxicity attributed to other methods of 
extending active life, such as the use of polyethylene glycol in PEGylated 
protein drug candidates. 
 
Importantly, this new patent means that Lipoxen's PolyXen  patent family now 
covers the creation of therapeutic conjugates utilising both the reducing end, 
as well as the non-reducing end, such methodologies having been shown in tests 
completed prior to both pre-clinical studies and clinical trials to avoid the 
problem of side product contamination. 
 
Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "This 
new PolyXen technology patent will protect Lipoxen's novel 
polysialylationtechnology into 2025. By applying this novel technology to its 
partners' therapeutic proteins, it is in the unique position delivering the 
benefits of polysialylation such as extending its active life plus the advantage 
of avoiding final product contamination. This forms an important part of 
Lipoxen's strategy to build its patent portfolio and secure long term value in 
the US, world's largest pharmaceutical market." 
 
                                    - Ends - 
 
For further information, please contact: 
Enquiries 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating / Claes Spång               |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon, Catherine Breen           |                    | 
+------------------------------------------+--------------------+ 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines.  Lipoxen has three proprietary patented 
technology platforms: 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
Lipoxen has multiple drug and vaccine programmes in development.  Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for blood coagulation drugs. 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities.  Lipoxen currently has commercial agreements with some 
of the world's leading biotechnology and pharmaceutical companies including 
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009. This fundraising was followed up by a GBP1.2 million placing in April 2010 
which was led by the Company's management team. 
 
Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock 
Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCEVLFFBQFZBBL
Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024